Response to: topical cyclosporine A 0.05% before and after surgery to prevent pterygium recurrence
Goksu Alacamli, Roberta Lilian Fernandes de Sousa Meneghim, Larissa Horikawa Satto, Kryscia Leiko Natsuaki, Alessandro Carvalho de Oliveira, Carlos Roberto Padovani, Magda Massae Hata Viveiros, Silvana Artioli Schellini

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCorneal Surgery and Treatments · Mast cells and histamine
Dear Editor,
We have read with interest the article by Roberta Lilian Fernandes de Sousa Meneghim et al.^(1)^. In response to this article^(1)^ which is a well-thought out and written paper, I would like to draw attention to some critical points in this study. As presented in most studies, topical cyclosporine drops require at least 3-6 months for their effectiveness to begin^(2-4)^. In the article by Meneghim et al.^(1)^, topical cyclosporine was used for only 10 days before and after the operation. In our clinic, Mugla Education and Research Hospital, we prescribe topical cyclosporine 3 months before and 6 months after the pterygium operation. In this article^(1)^, it seemed obvious that topical cyclosporine used for such a short time before and after the operation would not have a statistical or clinical effect.
Pterygium pathogenesis has been mainly associated with ultraviolet light exposure; however, this association remains quite controversial. The complete pathophysiology of pterygium also remains to be clarified^(5)^. To reduce recurrences, new study and treatment methods are needed.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Meneghim RLFS Satto LH Natsuaki KL Oliveira AC Padovani CR Viveiros MMH Topical cyclosporine A 0.05% before and after surgery to prevent pterygium recurrence Arq Bras Oftalmol 20198253723763127156910.5935/0004-2749.20190075 · doi ↗ · pubmed ↗
- 2de Paiva CS Pflugfelder SC Ng SM Akpek EK. Topical cyclosporine A therapy for dry eye syndrome Cochrane Database Syst Rev[Internet]2019 cited 21 sep 202099 CD 010051 Avaılable from: Topical cyclosporine A therapy for dry eye syndrome - de Paiva, CS - 2019 | Cochrane Library 3151798810.1002/14651858.CD 010051.pub 2PMC 6743670 · doi ↗ · pubmed ↗
- 3Özülken K KoçM Ayar O Hasiripi H. Topical cyclosporine A administration after pterygium surgery Eur J Ophthalmol 201222 Suppl 7S 5102172593710.5301/ejo.5000004 · doi ↗ · pubmed ↗
- 4Hwang S Choi S. A comparative study of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery Korean J Ophthalmol 20152963753812663545310.3341/kjo.2015.29.6.375PMC 4668252 · doi ↗ · pubmed ↗
- 5Wanzeler ACV Barbosa IA Duarte B Borges D Barbosa EB Kamiji D Mechanisms and biomarker candidates in pterygium development Arq Bras Oftalmol 20198265285363157692710.5935/0004-2749.20190103 · doi ↗ · pubmed ↗
- 6Shahraki T Arabi A Feizi S Pterygium: an update on pathophysiology, clinical features, and management Ther Adv Ophthalmol.202113251584142110201523410487110.1177/25158414211020152 PMC 8170279 · doi ↗ · pubmed ↗
- 7Viveiros MM Kakizaki FY Hercules LA Padovani CR Candeias JM Schellini SA In vitro study of cyclosporine A 0.05% on primary and recurrent pterygium fibroblasts Int Ophthalmol 2016362237422626035810.1007/s 10792-015-0106-2 · doi ↗ · pubmed ↗
- 8Kim YH Jung JC Gum S Park SB Ma JY Kim Y Inhibition of pterygium fibroblast migration and outgrowth by bevacizumab and cyclosporine A involves down-regulation of matrix metalloproteinases- 3 and -13P Lo S One 201712 e 016967510.1371/journal.pone.016967528068383 PMC 5221804 · doi ↗ · pubmed ↗
